---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-132524"
form_type: "8-K"
ticker: "AKTS"
cik: "0002035832"
company_name: "Aktis Oncology, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:28:12.008549+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aktis Oncology: FDA clears IND for AKY-2519; full-year 2025 net loss widens to $63.7M

## Summary
- FDA cleared IND for AKY-2519 (B7-H3 miniprotein radioconjugate); Phase 1b trial for solid tumors expected mid-2026.
- AKY-1189 (Nectin-4) granted Fast Track designation for urothelial cancer in Feb 2026; Phase 1b enrolling.
- Pro forma cash of $562.1M (incl. $335.3M net from Jan 2026 IPO) expected to fund operations into 2029.
- FY2025 net loss $63.7M vs $44.0M; R&D spend $67.5M (+65% YoY) driven by clinical advancement.
- Collaboration revenue from Eli Lilly partnership totaled $6.5M in FY2025, up from $1.5M in FY2024.

## SEC filing metadata
- accession: 0001193125-26-132524
- form_type: 8-K
- ticker: AKTS
- cik: 0002035832
- company_name: Aktis Oncology, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2035832/000119312526132524/0001193125-26-132524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2035832/000119312526132524/ck0002035832-20260330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-132524
- JSON: https://secwatch.observer/filing/0001193125-26-132524.json
- Plain text: https://secwatch.observer/filing/0001193125-26-132524.txt

## Key facts
- Earnings Releases
  Aktis Oncology, Inc. reported the year ended December 31, 2025 results: revenue $6.5 million.
  - Period: the year ended December 31, 2025
  - Revenue: $6.5 million
  - Result: reported results
  source text: the January 2026 IPO. The Company believes that the pro forma as adjusted cash position will fund its operations into 2029. • Collaboration revenue: Collaboration revenue was $6.5 million for the year ended December 31, 2025, compared to $1.5 million for the year ended December 31, 2024. The increase was attributable to revenue recognized under the Company’s
  evidence_url: https://www.sec.gov/Archives/edgar/data/2035832/000119312526132524/0001193125-26-132524-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.